Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
01 Dec 2023
Historique:
received: 07 02 2023
revised: 27 09 2023
medline: 4 12 2023
pubmed: 17 11 2023
entrez: 16 11 2023
Statut: epublish

Résumé

The fibroblast activation protein (FAP) is highly expressed on carcinoma-associated fibroblasts in the stroma of pancreatic cancer and thus is a promising target for imaging and therapy. Preliminary data on PET imaging with radiolabeled FAP inhibitors (FAPIs) demonstrate superior tumor detection. Here we assess the accuracy of FAP-directed PET in patients with pancreatic cancer.

Identifiants

pubmed: 37973185
pii: jnumed.122.264827
doi: 10.2967/jnumed.122.264827
doi:

Substances chimiques

Gallium Radioisotopes 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
Quinolines 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1910-1917

Informations de copyright

© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Auteurs

Lukas Kessler (L)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.

Nader Hirmas (N)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.

Kim M Pabst (KM)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Rainer Hamacher (R)

German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.
Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.

Justin Ferdinandus (J)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.

Benedikt M Schaarschmidt (BM)

Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.

Aleksandar Milosevic (A)

Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.

Michael Nader (M)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Lale Umutlu (L)

Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.

Waldemar Uhl (W)

Department of General and Visceral Surgery, St. Josef Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.

Anke Reinacher-Schick (A)

Department of Hematology and Oncology with Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.

Celine Lugnier (C)

Department of General and Visceral Surgery, Alfried Krupp Hospital, Essen, Germany.

David Witte (D)

Department of General and Visceral Surgery, Alfried Krupp Hospital, Essen, Germany.

Marco Niedergethmann (M)

Department of General and Visceral Surgery, Alfried Krupp Hospital, Essen, Germany.

Ken Herrmann (K)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.

Wolfgang P Fendler (WP)

Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Wolfgang.fendler@uk-essen.de jens.siveke@uk-essen.de.
German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.

Jens T Siveke (JT)

German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany; Wolfgang.fendler@uk-essen.de jens.siveke@uk-essen.de.
Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; and.
Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH